Sandbox:Cherry: Difference between revisions

Jump to navigation Jump to search
← Older editNewer edit →
VisualWikitext
Sudarshana Datta (talk | contribs)
nocaptcha
3,577 edits
No edit summary
Sudarshana Datta (talk | contribs)
nocaptcha
3,577 edits
No edit summary
Line 1: Line 1:
In patients with pancreatic cancer, surgery is the primary modality of treatment.
In patients with pancreatic cancer, surgery is the primary modality of treatment.
Extrapancreatic disease requires palliative therapy and curative resection is not performed in such patients.Patients with unresectable disease are treated with chemotherapy and/or radiation therapy as a part of adjuvant or neoadjuvant therapy.
Extrapancreatic disease requires palliative therapy and curative resection is not performed in such patients.Patients with unresectable disease are treated with chemotherapy and/or radiation therapy as a part of adjuvant or neoadjuvant therapy.
Curative resection is not contraindicated in all patients with vascular invasion. Involvement of the portal or superior mesenteric vein can be resected and reconstructed with the help of splenic, saphenous or internal jugular veins. However, the involvement of arteries such as the hepatic, celiac or superior mesenteric are contraindications to resection.
Curative resection is not contraindicated in all patients with vascular invasion.<ref name="pmid17632763">{{cite journal |vauthors=Al-Haddad M, Martin JK, Nguyen J, Pungpapong S, Raimondo M, Woodward T, Kim G, Noh K, Wallace MB |title=Vascular resection and reconstruction for pancreatic malignancy: a single center survival study |journal=J. Gastrointest. Surg. |volume=11 |issue=9 |pages=1168–74 |year=2007 |pmid=17632763 |doi=10.1007/s11605-007-0216-x |url=}}</ref>
Involvement of the portal or superior mesenteric vein can be resected and reconstructed with the help of splenic, saphenous or internal jugular veins. However, the involvement of arteries such as the hepatic, celiac or superior mesenteric are contraindications to resection.
Various methods of surgical resection may be employed and each of these has its own sets of risks and perioperative complications. The facts are discussed by the patient and surgical team before arriving at a well-informed decision.
Various methods of surgical resection may be employed and each of these has its own sets of risks and perioperative complications. The facts are discussed by the patient and surgical team before arriving at a well-informed decision.
The method of surgical resection depends on the following features:
The method of surgical resection depends on the following features:
Line 12: Line 13:
*Pancreaticoduodenectomy, where pylorus may or may not be spared on an individual basis
*Pancreaticoduodenectomy, where pylorus may or may not be spared on an individual basis


The National Comprehensive Cancer Network (NCCN) has recommended certain guidelines on resectability of pancreatic neoplasms:
The National Comprehensive Cancer Network (NCCN) has recommended certain guidelines on resectability of pancreatic neoplasms:<ref name="pmid28948329">{{cite journal |vauthors=Fonseca AL, Fleming JB |title=Surgery for pancreatic cancer: critical radiologic findings for clinical decision making |journal=Abdom Radiol (NY) |volume= |issue= |pages= |year=2017 |pmid=28948329 |doi=10.1007/s00261-017-1332-z |url=}}</ref>
*Patient selection is based on:
*Patient selection is based on:
**Resection margins  
**Resection margins  
Line 19: Line 20:
**Comorbidities
**Comorbidities
   
   
European Society for Medical Oncology (ESMO) has certain guidelines on the treatment of metastatic pancreatic cancer:
European Society for Medical Oncology (ESMO) has certain guidelines on the treatment of metastatic pancreatic cancer:<ref name="pmid26314780">{{cite journal |vauthors=Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D |title=Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up |journal=Ann. Oncol. |volume=26 Suppl 5 |issue= |pages=v56–68 |year=2015 |pmid=26314780 |doi=10.1093/annonc/mdv295 |url=}}</ref>
*Chemotherapy not preferred
*Chemotherapy not preferred
*Gemcitabine is preferred over 5 FU
*Gemcitabine is preferred over 5 FU
*Treatment is symptomatic with bypass surgery or stent placement for gastric outlet obstruction or obstructive jaundice
*Treatment is symptomatic with bypass surgery or stent placement for gastric outlet obstruction or obstructive jaundice
   
   
In case of locally advanced disease which is unresectable, the following methods of treatment are preferred:
In case of locally advanced disease which is unresectable, the following methods of treatment are preferred:<ref name="pmid25524417">{{cite journal |vauthors=Rombouts SJ, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG, Molenaar IQ |title=Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer |journal=Br J Surg |volume=102 |issue=3 |pages=182–93 |year=2015 |pmid=25524417 |doi=10.1002/bjs.9716 |url=}}</ref><ref name="pmid25524417">{{cite journal |vauthors=Rombouts SJ, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG, Molenaar IQ |title=Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer |journal=Br J Surg |volume=102 |issue=3 |pages=182–93 |year=2015 |pmid=25524417 |doi=10.1002/bjs.9716 |url=}}</ref>
Microwave ablation
Microwave ablation
Photodynamic therapy
Photodynamic therapy
Line 37: Line 38:
CHEMOTHERAPY
CHEMOTHERAPY


Metastatic disease/ Advanced pancreatic cancer which is unresectable:
Metastatic disease/ Advanced pancreatic cancer which is unresectable:<ref name="pmid28222309">{{cite journal |vauthors=Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E |title=Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group |journal=Eur. J. Cancer |volume=75 |issue= |pages=73–82 |year=2017 |pmid=28222309 |doi=10.1016/j.ejca.2016.12.032 |url=}}</ref><ref name="pmid28259610">{{cite journal |vauthors=Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP |title=Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial |journal=Lancet Oncol. |volume=18 |issue=4 |pages=486–499 |year=2017 |pmid=28259610 |doi=10.1016/S1470-2045(17)30084-0 |url=}}</ref><ref name="pmid28105634">{{cite journal |vauthors=Xia BT, Fu B, Wang J, Kim Y, Ahmad SA, Dhar VK, Levinsky NC, Hanseman DJ, Habib DA, Wilson GC, Smith M, Olowokure OO, Kharofa J, Al Humaidi AH, Choe KA, Abbott DE, Ahmad SA |title=Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy? |journal=J Surg Oncol |volume=115 |issue=4 |pages=376–383 |year=2017 |pmid=28105634 |doi=10.1002/jso.24538 |url=}}</ref><ref name="pmid27484349">{{cite journal |vauthors=Choi SJ, Kim HJ, Kim JS, Bak YT, Kim JS |title=Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report |journal=BMC Cancer |volume=16 |issue= |pages=588 |year=2016 |pmid=27484349 |pmc=4971692 |doi=10.1186/s12885-016-2616-3 |url=}}</ref><ref name="pmid27358556">{{cite journal |vauthors=Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH |title=Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis |journal=Drug Des Devel Ther |volume=10 |issue= |pages=1961–72 |year=2016 |pmid=27358556 |pmc=4912328 |doi=10.2147/DDDT.S105442 |url=}}</ref><ref name="pmid27139057">{{cite journal |vauthors=Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C |title=Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial |journal=JAMA |volume=315 |issue=17 |pages=1844–53 |year=2016 |pmid=27139057 |doi=10.1001/jama.2016.4324 |url=}}</ref><ref name="pmid26929778">{{cite journal |vauthors=Chen J, Kaley K, Garcon MC, Rodriguez T, Saif MW |title=A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series |journal=Therap Adv Gastroenterol |volume=9 |issue=2 |pages=162–8 |year=2016 |pmid=26929778 |pmc=4749861 |doi=10.1177/1756283X15622779 |url=}}</ref>
The National Comprehensive Cancer Network (NCCN) has recommended guidelines for treatment in patients based on their performance status.
The National Comprehensive Cancer Network (NCCN) has recommended guidelines for treatment in patients based on their performance status.
In order to predict survival of patients in various stages of pancreatic cancer, the performance status of a patient is a major prognostic factor. Patients with poor prognostic factors have poor performance status. This includes-<ref name="pmid22996141">{{cite journal |vauthors=Tas F, Sen F, Odabas H, Kılıc L, Keskın S, Yıldız I |title=Performance status of patients is the major prognostic factor at all stages of pancreatic cancer |journal=Int. J. Clin. Oncol. |volume=18 |issue=5 |pages=839–46 |year=2013 |pmid=22996141 |doi=10.1007/s10147-012-0474-9 |url=}}</ref>
In order to predict survival of patients in various stages of pancreatic cancer, the performance status of a patient is a major prognostic factor. Patients with poor prognostic factors have poor performance status. This includes-<ref name="pmid22996141">{{cite journal |vauthors=Tas F, Sen F, Odabas H, Kılıc L, Keskın S, Yıldız I |title=Performance status of patients is the major prognostic factor at all stages of pancreatic cancer |journal=Int. J. Clin. Oncol. |volume=18 |issue=5 |pages=839–46 |year=2013 |pmid=22996141 |doi=10.1007/s10147-012-0474-9 |url=}}</ref>
Line 52: Line 53:
Preferred treatment: Capecitabine or capecitabine+erlotinib
Preferred treatment: Capecitabine or capecitabine+erlotinib
One year survival of FOLFIRINOX (leucovorin+5-lfuorouracil [LV5-FU]+oxaliplatin+irinotecan)>Gemcitabine
One year survival of FOLFIRINOX (leucovorin+5-lfuorouracil [LV5-FU]+oxaliplatin+irinotecan)>Gemcitabine
One year survival of Gemcitabine+ Erlotinib> Gemcitabine
One year survival of Gemcitabine+ Erlotinib> Gemcitabine<ref name="pmid28541474">{{cite journal |vauthors=Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T |title=Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis |journal=Jpn. J. Clin. Oncol. |volume=47 |issue=9 |pages=832–839 |year=2017 |pmid=28541474 |doi=10.1093/jjco/hyx075 |url=}}</ref><ref name="pmid28702772">{{cite journal |vauthors=Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R |title=A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent |journal=Cancer Chemother. Pharmacol. |volume= |issue= |pages= |year=2017 |pmid=28702772 |doi=10.1007/s00280-017-3375-9 |url=}}</ref>
One year survival of Gemcitabine+ Capecitabine≥Gemcitabine   
One year survival of Gemcitabine+ Capecitabine≥Gemcitabine   
One year survival of Gemcitabine+ nanoparticle albumin-bound (nab)-paclitaxel> Gemcitabine
One year survival of Gemcitabine+ nanoparticle albumin-bound (nab)-paclitaxel> Gemcitabine

Revision as of 04:07, 13 November 2017

In patients with pancreatic cancer, surgery is the primary modality of treatment. Extrapancreatic disease requires palliative therapy and curative resection is not performed in such patients.Patients with unresectable disease are treated with chemotherapy and/or radiation therapy as a part of adjuvant or neoadjuvant therapy. Curative resection is not contraindicated in all patients with vascular invasion.[1] 

Involvement of the portal or superior mesenteric vein can be resected and reconstructed with the help of splenic, saphenous or internal jugular veins. However, the involvement of arteries such as the hepatic, celiac or superior mesenteric are contraindications to resection.

Various methods of surgical resection may be employed and each of these has its own sets of risks and perioperative complications. The facts are discussed by the patient and surgical team before arriving at a well-informed decision. The method of surgical resection depends on the following features:

  • Locally invasive characteristics of the neoplasm
  • Size
  • Location

Methods of curative resection options include:

    • Distal Pancreatectomy
  • Total pancreatectomy
  • Pancreaticoduodenectomy, where pylorus may or may not be spared on an individual basis

The National Comprehensive Cancer Network (NCCN) has recommended certain guidelines on resectability of pancreatic neoplasms:[2]

  • Patient selection is based on:
    • Resection margins
    • High probability of cure
    • Patient's age
    • Comorbidities

European Society for Medical Oncology (ESMO) has certain guidelines on the treatment of metastatic pancreatic cancer:[3]

  • Chemotherapy not preferred
  • Gemcitabine is preferred over 5 FU
  • Treatment is symptomatic with bypass surgery or stent placement for gastric outlet obstruction or obstructive jaundice

In case of locally advanced disease which is unresectable, the following methods of treatment are preferred:[4][4] Microwave ablation Photodynamic therapy Irreversible electroporation Photodynamic therapy High-intensity focused ultrasound (HIFU) Iodine-125–cryosurgery Iodine-125 Stereotactic body radiation therapy (SBRT) Radiofrequency ablation (RFA)

CHEMOTHERAPY

Metastatic disease/ Advanced pancreatic cancer which is unresectable:[5][6][7][8][9][10][11] The National Comprehensive Cancer Network (NCCN) has recommended guidelines for treatment in patients based on their performance status. In order to predict survival of patients in various stages of pancreatic cancer, the performance status of a patient is a major prognostic factor. Patients with poor prognostic factors have poor performance status. This includes-[12] Metastatic disease Large tumor Severe weight loss In patients with locally advanced unresectable or metastatic disease with good performance status Preferred treatment: FOLFIRINOX In patients with locally advanced unresectable or metastatic disease with good performance status with intolerance to FOLFIRINOX Preferred treatment:Paclitaxel protein bound+ Gemcitabine In patients with locally advanced unresectable or metastatic disease with poor performance status Preferred treatment: Gemcitabine monotherapy In patients with locally advanced unresectable or metastatic disease with poor performance status refractory to Gemcitabine: Preferred treatment: Capecitabine or capecitabine+erlotinib One year survival of FOLFIRINOX (leucovorin+5-lfuorouracil [LV5-FU]+oxaliplatin+irinotecan)>Gemcitabine One year survival of Gemcitabine+ Erlotinib> Gemcitabine[13][14] One year survival of Gemcitabine+ Capecitabine≥Gemcitabine One year survival of Gemcitabine+ nanoparticle albumin-bound (nab)-paclitaxel> Gemcitabine


NEW TREATMENTS 

Irinotecan in an encapsulated form inside a nanoliposome is being used in advanced pancreatic cancer patients who have been earlier been treated using gemcitabine-based chemotherapy.

Liposomal Irinotecan is used along with leucovorin and fluorouracil.


ADJUVANT THERAPY The use of gemcitabine as adjuvant therapy is considered a standard form of therapy following surgical resection in pancreatic cancer patients. NEOADJUVANT THERAPY Neoadjuvant therapy may be used as a form of therapy due to the following reasons: Toxic effects of chemotherapy can be tolerated more easily before surgery as compared to after resection Shrinkage of tumor with neoadjuvant therapy makes resection easier and improves patient prognosis Systemic treatment for cancer involving various systems improves prognosis No therapy is considered as first line therapy under this category.Decisions for treatment are made on an individual basis.

SURGERY

Pancreaticoduodenectomy (Whipple Procedure) It is mainly performed for tumors located in: Periampullary region Duodenum Bile duct (Cholangiocarcinoma) Pancreatic duct Head of pancreas Whipple procedure involves removal of the following components due to common blood supply: Stomach antrum Gallbladder Duodenum Head of pancreas After removal of the above structures, the biliary and distal pancreatic ducts are anastomosed to the jejunum to facilitate surgical drainage. 

This procedure is associated with several morbidities:

Postoperative abcess Wound infection Anastomotic leak Delay in gastric emptying

Pylorus sparing Whipple procedure: The pylorus may be spared as a modification of Whipple procedure to decrease gastric emptying due to antrectomy. This significantly reduces the incidence of nutritional deficiencies arising from this surgery.


The European Society for Medical Oncology states that the only curative therapy is surgical resection. Ten percent is the five year survival of patients with pancreatic cancer. Patients with node-positive tumors have very poor long term survival.

Distal Pancreatectomy This procedure has a limited use in curative resection of pancreatic cancer. It is mainly performed for tumors located in: Body of pancreas Tail of pancreas This form of surgery has fewer morbidities than the Whipple procedure.


Distal Pancreatectomy involves the following components: 

Separation of the distal pancreas bearing the tumor from the normal tissue
Resection of the affected portion

Oversewing of the distal pancreatic duct 

This procedure is associated with several morbidities:

Pancreatic endocrine insufficiency Bleeding Leakage of pancreatic stump

Total Pancreatectomy


It is the least preferred due to high mortality rate. It is mainly performed for tumors located in: Neck of the pancreas. Due to involvement of neck, patients develop insulin dependent DM.

PALLIATIVE THERAPY

Pain There are various techniques for pain management as palliative therapy in patients:

Narcotic analgesics Narcotic analgesics+ tricyclic antidepressants/ antiemetics Endoscopic decompression with stent placement in patients with biliary or pancreatic duct obstruction Radiation therapy Neurolysis of the celiac ganglia by many approaches Intraoperative 

transgastric
transthoracic 
transabdominal

Jaundice Obstructive jaundice can present with features of cholangitis: Fever and chills Nausea, vomitting Clay coloured stools Dark urine yellowish discolration of skin pruritus 

right upper quadrant pain

Anorexia Preferred treatment in patients: Endoscopic decompression with stent placement in patients with biliary obstruction Techniques of biliary decompression: Cholecystojejunostomy Choledochojejunostomy

Types of stents: Metal- costly, longer lifespan Plastic- cheaper, need replacement every three months

Duodenal obstruction Preferred treatment: Endoscopic stenting of duodenal obstruction Gastrojejunostomy

  1. ↑ Al-Haddad M, Martin JK, Nguyen J, Pungpapong S, Raimondo M, Woodward T, Kim G, Noh K, Wallace MB (2007). "Vascular resection and reconstruction for pancreatic malignancy: a single center survival study". J. Gastrointest. Surg. 11 (9): 1168–74. doi:10.1007/s11605-007-0216-x. PMID 17632763.
  2. ↑ Fonseca AL, Fleming JB (2017). "Surgery for pancreatic cancer: critical radiologic findings for clinical decision making". Abdom Radiol (NY). doi:10.1007/s00261-017-1332-z. PMID 28948329.
  3. ↑ Ducreux M, Cuhna AS, Caramella C, Hollebecque A, Burtin P, Goéré D, Seufferlein T, Haustermans K, Van Laethem JL, Conroy T, Arnold D (2015). "Cancer of the pancreas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up". Ann. Oncol. 26 Suppl 5: v56–68. doi:10.1093/annonc/mdv295. PMID 26314780.
  4. ↑ 4.0 4.1 Rombouts SJ, Vogel JA, van Santvoort HC, van Lienden KP, van Hillegersberg R, Busch OR, Besselink MG, Molenaar IQ (2015). "Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer". Br J Surg. 102 (3): 182–93. doi:10.1002/bjs.9716. PMID 25524417.
  5. ↑ Irigoyen A, Gallego J, Guillén Ponce C, Vera R, Iranzo V, Ales I, Arévalo S, Pisa A, Martín M, Salud A, Falcó E, Sáenz A, Manzano Mozo JL, Pulido G, Martínez Galán J, Pazo-Cid R, Rivera F, García García T, Serra O, Fernández Parra EM, Hurtado A, Gómez Reina MJ, López Gomez LJ, Martínez Ortega E, Benavides M, Aranda E (2017). "Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group". Eur. J. Cancer. 75: 73–82. doi:10.1016/j.ejca.2016.12.032. PMID 28222309.
  6. ↑ Middleton G, Palmer DH, Greenhalf W, Ghaneh P, Jackson R, Cox T, Evans A, Shaw VE, Wadsley J, Valle JW, Propper D, Wasan H, Falk S, Cunningham D, Coxon F, Ross P, Madhusudan S, Wadd N, Corrie P, Hickish T, Costello E, Campbell F, Rawcliffe C, Neoptolemos JP (2017). "Vandetanib plus gemcitabine versus placebo plus gemcitabine in locally advanced or metastatic pancreatic carcinoma (ViP): a prospective, randomised, double-blind, multicentre phase 2 trial". Lancet Oncol. 18 (4): 486–499. doi:10.1016/S1470-2045(17)30084-0. PMID 28259610.
  7. ↑ Xia BT, Fu B, Wang J, Kim Y, Ahmad SA, Dhar VK, Levinsky NC, Hanseman DJ, Habib DA, Wilson GC, Smith M, Olowokure OO, Kharofa J, Al Humaidi AH, Choe KA, Abbott DE, Ahmad SA (2017). "Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?". J Surg Oncol. 115 (4): 376–383. doi:10.1002/jso.24538. PMID 28105634.
  8. ↑ Choi SJ, Kim HJ, Kim JS, Bak YT, Kim JS (2016). "Radiation recall gastritis secondary to combination of gemcitabine and erlotinib in pancreatic cancer and response to PPI - a case report". BMC Cancer. 16: 588. doi:10.1186/s12885-016-2616-3. PMC 4971692. PMID 27484349.
  9. ↑ Wang Y, Hu GF, Zhang QQ, Tang N, Guo J, Liu LY, Han X, Wang X, Wang ZH (2016). "Efficacy and safety of gemcitabine plus erlotinib for locally advanced or metastatic pancreatic cancer: a systematic review and meta-analysis". Drug Des Devel Ther. 10: 1961–72. doi:10.2147/DDDT.S105442. PMC 4912328. PMID 27358556.
  10. ↑ Hammel P, Huguet F, van Laethem JL, Goldstein D, Glimelius B, Artru P, Borbath I, Bouché O, Shannon J, André T, Mineur L, Chibaudel B, Bonnetain F, Louvet C (2016). "Effect of Chemoradiotherapy vs Chemotherapy on Survival in Patients With Locally Advanced Pancreatic Cancer Controlled After 4 Months of Gemcitabine With or Without Erlotinib: The LAP07 Randomized Clinical Trial". JAMA. 315 (17): 1844–53. doi:10.1001/jama.2016.4324. PMID 27139057.
  11. ↑ Chen J, Kaley K, Garcon MC, Rodriguez T, Saif MW (2016). "A novel schedule of erlotinib/capecitabine (7/7) as salvage therapy in previously treated advanced pancreatic adenocarcinoma: a case series". Therap Adv Gastroenterol. 9 (2): 162–8. doi:10.1177/1756283X15622779. PMC 4749861. PMID 26929778.
  12. ↑ Tas F, Sen F, Odabas H, Kılıc L, Keskın S, Yıldız I (2013). "Performance status of patients is the major prognostic factor at all stages of pancreatic cancer". Int. J. Clin. Oncol. 18 (5): 839–46. doi:10.1007/s10147-012-0474-9. PMID 22996141.
  13. ↑ Furuse J, Gemma A, Ichikawa W, Okusaka T, Seki A, Ishii T (2017). "Postmarketing surveillance study of erlotinib plus gemcitabine for pancreatic cancer in Japan: POLARIS final analysis". Jpn. J. Clin. Oncol. 47 (9): 832–839. doi:10.1093/jjco/hyx075. PMID 28541474.
  14. ↑ Fountzilas C, Chhatrala R, Khushalani N, Tan W, LeVea C, Hutson A, Tucker C, Ma WW, Warren G, Boland P, Iyer R (2017). "A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent". Cancer Chemother. Pharmacol. doi:10.1007/s00280-017-3375-9. PMID 28702772.
Retrieved from "https://www.wikidoc.org/index.php?title=Sandbox:Cherry&oldid=1387721"